JP6968094B2 - ヘテロアリール置換されたピリジン類及び使用方法 - Google Patents

ヘテロアリール置換されたピリジン類及び使用方法 Download PDF

Info

Publication number
JP6968094B2
JP6968094B2 JP2018552704A JP2018552704A JP6968094B2 JP 6968094 B2 JP6968094 B2 JP 6968094B2 JP 2018552704 A JP2018552704 A JP 2018552704A JP 2018552704 A JP2018552704 A JP 2018552704A JP 6968094 B2 JP6968094 B2 JP 6968094B2
Authority
JP
Japan
Prior art keywords
formula
substituted
sulfonyl
amino
trifluoromethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018552704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517455A5 (enExample
JP2019517455A (ja
Inventor
アルテンバック，ロバート・ジェイ
ボグダン，アンドリュー
コーチ，ジュバンニ・ペトル・ディウニス
コワート，マーロン・ディー
グレスツラー，スティーブン・エヌ
ケルグテルマンス，ハンス
キム，フィリップ・アール
ファン・デル・プラス，スティーブン・エミエル
ワン，シュエチン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of JP2019517455A publication Critical patent/JP2019517455A/ja
Publication of JP2019517455A5 publication Critical patent/JP2019517455A5/ja
Priority to JP2021173679A priority Critical patent/JP7392211B2/ja
Application granted granted Critical
Publication of JP6968094B2 publication Critical patent/JP6968094B2/ja
Priority to JP2023049450A priority patent/JP7622122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018552704A 2016-06-03 2017-05-24 ヘテロアリール置換されたピリジン類及び使用方法 Active JP6968094B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021173679A JP7392211B2 (ja) 2016-06-03 2021-10-25 ヘテロアリール置換されたピリジン類及び使用方法
JP2023049450A JP7622122B2 (ja) 2016-06-03 2023-03-27 ヘテロアリール置換されたピリジン類及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345315P 2016-06-03 2016-06-03
US62/345,315 2016-06-03
PCT/IB2017/053068 WO2017208115A1 (en) 2016-06-03 2017-05-24 Heteroaryl substituted pyridines and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021173679A Division JP7392211B2 (ja) 2016-06-03 2021-10-25 ヘテロアリール置換されたピリジン類及び使用方法

Publications (3)

Publication Number Publication Date
JP2019517455A JP2019517455A (ja) 2019-06-24
JP2019517455A5 JP2019517455A5 (enExample) 2020-06-25
JP6968094B2 true JP6968094B2 (ja) 2021-11-17

Family

ID=59014678

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018552704A Active JP6968094B2 (ja) 2016-06-03 2017-05-24 ヘテロアリール置換されたピリジン類及び使用方法
JP2021173679A Active JP7392211B2 (ja) 2016-06-03 2021-10-25 ヘテロアリール置換されたピリジン類及び使用方法
JP2023049450A Active JP7622122B2 (ja) 2016-06-03 2023-03-27 ヘテロアリール置換されたピリジン類及び使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021173679A Active JP7392211B2 (ja) 2016-06-03 2021-10-25 ヘテロアリール置換されたピリジン類及び使用方法
JP2023049450A Active JP7622122B2 (ja) 2016-06-03 2023-03-27 ヘテロアリール置換されたピリジン類及び使用方法

Country Status (34)

Country Link
US (2) US10138227B2 (enExample)
EP (1) EP3464282B1 (enExample)
JP (3) JP6968094B2 (enExample)
KR (2) KR102469995B1 (enExample)
CN (2) CN109311864B (enExample)
AR (2) AR108672A1 (enExample)
AU (3) AU2017273215B2 (enExample)
CL (1) CL2018003323A1 (enExample)
CO (1) CO2018012171A2 (enExample)
CR (1) CR20180547A (enExample)
CY (1) CY1124031T1 (enExample)
DK (1) DK3464282T3 (enExample)
DO (1) DOP2018000257A (enExample)
EC (1) ECSP18094790A (enExample)
ES (1) ES2806873T3 (enExample)
HR (1) HRP20201068T1 (enExample)
HU (1) HUE050248T2 (enExample)
IL (3) IL288243B2 (enExample)
LT (1) LT3464282T (enExample)
MX (2) MX385054B (enExample)
MY (1) MY199604A (enExample)
PE (1) PE20190511A1 (enExample)
PH (1) PH12018502534B1 (enExample)
PL (1) PL3464282T3 (enExample)
PT (1) PT3464282T (enExample)
RS (1) RS60574B1 (enExample)
RU (1) RU2756743C2 (enExample)
SG (1) SG11201808842VA (enExample)
SI (1) SI3464282T1 (enExample)
SM (1) SMT202000394T1 (enExample)
TW (4) TWI752961B (enExample)
UY (2) UY37272A (enExample)
WO (1) WO2017208115A1 (enExample)
ZA (1) ZA201808423B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022009448A (ja) * 2016-06-03 2022-01-14 アッヴィ・エス・ア・エール・エル ヘテロアリール置換されたピリジン類及び使用方法

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100921397B1 (ko) * 2009-02-09 2009-10-14 (주)오엠티 인쇄회로기판의 세척장비 및 이를 이용한 세척방법
TW202140422A (zh) 2014-10-06 2021-11-01 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
GEP20217329B (en) 2016-09-30 2021-12-10 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EA202192783A1 (ru) 2016-12-09 2022-02-24 Вертекс Фармасьютикалз Инкорпорейтед Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
WO2018116185A1 (en) 2016-12-20 2018-06-28 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
MA54105A (fr) 2017-06-08 2021-09-15 Vertex Pharma Méthodes de traitement de la fibrose kystique
IL272032B2 (en) 2017-07-17 2026-04-01 Vertex Pharma Combination therapy for the treatment of cystic fibrosis including N-(1,3-DIMETHYLPYRAZOL-4-YL)SULFONYL-6-[3-(3,3,3-TRIFLUORO-2,2- DIMETHYL-PROPOXY)PYRAZOL-1-YL]-2-[(4S)-2,2,4- TRIMETHYLPYRROLIDIN-1-YL]PYRIDINE-3-CARBOXAMIDE and
MA49752A (fr) 2017-08-02 2021-04-21 Vertex Pharma Procédés de préparation de composés de pyrrolidine
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
RS64018B1 (sr) 2018-02-15 2023-03-31 Vertex Pharma Makrocikli kao modulatori transmembranskog regulatora provodnosti cistične fibroze, njihove farmaceutske kompozicije, njihova upotreba u lečenju cistične fibroze i proces njihove izrade
US10710994B2 (en) * 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
IT201900000687A1 (it) * 2019-01-16 2020-07-16 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento della fibrosi cistica
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
US11345691B2 (en) 2019-06-03 2022-05-31 AbbVie Global Enterprises Ltd. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2021011327A1 (en) 2019-07-12 2021-01-21 Orphomed, Inc. Compound for treating cystic fibrosis
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
US11873300B2 (en) 2019-08-14 2024-01-16 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
CA3158057A1 (en) * 2019-11-12 2021-05-20 Genzyme Corporation 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity
MX2022005810A (es) 2019-11-12 2022-06-08 Genzyme Corp Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de regulador de la conductancia transmembrana de la fibrosis quistica (cftr) deficiente.
WO2021113808A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Cftr-modulating arylamides
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2022036060A1 (en) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
CN122537531A (zh) 2020-08-20 2026-08-11 小利兰·斯坦福大学托管委员会 用于治疗以黏液分泌过多为特征的呼吸系统疾病的方法
US12612416B2 (en) 2020-10-07 2026-04-28 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MX2023006770A (es) 2020-12-10 2023-08-14 Vertex Pharma Metodos de tratamiento para fibrosis quistica.
EP4274828A1 (en) 2021-01-06 2023-11-15 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2022150173A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
CA3223599A1 (en) 2021-08-19 2023-02-23 Peter FINKBEINER Method for controlling diamide resistant pests & compounds therefor
WO2024056798A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators
CN119907667A (zh) 2022-09-15 2025-04-29 爱杜西亚药品有限公司 大环cftr调节剂与cftr校正剂和/或cftr增效剂的组合
CN116813569B (zh) * 2023-07-10 2024-07-02 衡阳市中心医院 一种抗癌药中间体的制备方法和抗癌药的制备方法
WO2025186214A1 (en) 2024-03-05 2025-09-12 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0509282A (pt) * 2004-03-30 2007-09-18 Univ California compostos contendo hidrazida inibidores de cftr e seus usos
WO2005120497A2 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
CA2881078C (en) 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
EP2142498A2 (en) * 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
CN101687883B (zh) 2007-05-25 2012-05-23 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
BRPI0820669A2 (pt) 2007-12-10 2020-08-04 Novartis Ag compostos orgânicos
ES2422741T3 (es) 2007-12-13 2013-09-13 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
NZ592504A (en) 2008-10-23 2013-04-26 Vertex Pharma Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
MX2011004375A (es) * 2008-10-23 2013-03-07 Vertex Pharma Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
EP2382197B1 (en) 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2011008931A2 (en) * 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
ES2553771T3 (es) 2010-10-08 2015-12-11 Nivalis Therapeutics, Inc. Nuevos compuestos de quinolina sustituidos como inhibidores de la S-nitrosoglutatión reductasa
WO2012154880A1 (en) * 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
JP6165733B2 (ja) * 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
CN103946221B (zh) * 2011-09-16 2016-08-03 诺华股份有限公司 用于治疗囊性纤维化的杂环化合物
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
BR112014006535A2 (pt) 2011-09-20 2017-03-28 Univ North Carolina Chapel Hill regulação dos canais de sódio através das proteínas plunc
CA3122383A1 (en) 2013-05-07 2014-11-13 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis.
AU2014304562B8 (en) 2013-08-08 2018-07-05 Galapagos Nv Thieno[2,3-c]pyrans as CFTR modulators
AU2015229117A1 (en) 2014-03-13 2016-09-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
US9642831B2 (en) 2014-10-31 2017-05-09 Abbvie S.Á.R.L. Substituted chromanes and method of use
CA2966023A1 (en) 2014-10-31 2016-05-06 Abbvie S.A.R.L. Substituted tetrahydropyrans and method of use
US10196384B2 (en) * 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
US10047051B2 (en) * 2015-06-02 2018-08-14 Abbvie S.Á.R.L. Substituted pyridines and method of use
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
AU2016333855A1 (en) 2015-10-09 2018-04-26 AbbVie S.à.r.l. Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use
PL3359541T3 (pl) 2015-10-09 2021-01-11 AbbVie Overseas S.à r.l. N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA
AU2017256172A1 (en) 2016-04-26 2018-09-06 AbbVie S.à.r.l. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022009448A (ja) * 2016-06-03 2022-01-14 アッヴィ・エス・ア・エール・エル ヘテロアリール置換されたピリジン類及び使用方法
JP7392211B2 (ja) 2016-06-03 2023-12-06 アッヴィ・グローバル・エンタープライザズ・リミテッド ヘテロアリール置換されたピリジン類及び使用方法
JP2023172889A (ja) * 2016-06-03 2023-12-06 アッヴィ・グローバル・エンタープライザズ・リミテッド ヘテロアリール置換されたピリジン類及び使用方法
JP7622122B2 (ja) 2016-06-03 2025-01-27 アッヴィ・グローバル・エンタープライザズ・リミテッド ヘテロアリール置換されたピリジン類及び使用方法

Also Published As

Publication number Publication date
AR108672A1 (es) 2018-09-12
AU2024202468A1 (en) 2024-05-02
RU2018138707A (ru) 2020-07-14
AU2021282409B2 (en) 2024-01-18
SI3464282T1 (sl) 2020-12-31
TW202515560A (zh) 2025-04-16
HUE050248T2 (hu) 2020-12-28
NZ788542A (en) 2025-06-27
PE20190511A1 (es) 2019-04-10
US20170349576A1 (en) 2017-12-07
EP3464282A1 (en) 2019-04-10
CA3022216A1 (en) 2017-12-07
IL262415B (en) 2021-12-01
MX2021009322A (es) 2021-09-08
DOP2018000257A (es) 2018-12-31
PH12018502534B1 (en) 2020-09-23
CN109311864A (zh) 2019-02-05
BR112018074815A2 (pt) 2019-03-19
IL303196A (en) 2023-07-01
DK3464282T3 (da) 2020-07-27
TW202329959A (zh) 2023-08-01
IL288243A (en) 2022-01-01
MX2018014758A (es) 2019-04-29
JP2022009448A (ja) 2022-01-14
TW202214614A (zh) 2022-04-16
IL288243B2 (en) 2023-11-01
JP7622122B2 (ja) 2025-01-27
CN114671864B (zh) 2025-04-08
CY1124031T1 (el) 2022-03-24
HRP20201068T1 (hr) 2020-11-13
US10138227B2 (en) 2018-11-27
LT3464282T (lt) 2020-09-10
CN109311864B (zh) 2022-05-10
TWI797926B (zh) 2023-04-01
WO2017208115A1 (en) 2017-12-07
UY37272A (es) 2018-01-02
RU2018138707A3 (enExample) 2020-08-24
PL3464282T3 (pl) 2020-12-14
CR20180547A (es) 2019-10-30
US10604515B2 (en) 2020-03-31
TWI752961B (zh) 2022-01-21
PT3464282T (pt) 2020-07-17
IL303196B1 (en) 2024-12-01
US20190055229A1 (en) 2019-02-21
JP2019517455A (ja) 2019-06-24
NZ747222A (en) 2025-06-27
MY199604A (en) 2023-11-08
CN114671864A (zh) 2022-06-28
KR20220162806A (ko) 2022-12-08
KR20190015215A (ko) 2019-02-13
RS60574B1 (sr) 2020-08-31
EP3464282B1 (en) 2020-04-22
KR102719916B1 (ko) 2024-10-23
CO2018012171A2 (es) 2018-11-30
IL303196B2 (en) 2025-04-01
AU2021282409A1 (en) 2021-12-23
SG11201808842VA (en) 2018-11-29
ES2806873T3 (es) 2021-02-18
PH12018502534A1 (en) 2019-10-21
IL288243B1 (en) 2023-07-01
AU2024202468B2 (en) 2026-07-02
RU2756743C2 (ru) 2021-10-05
AU2017273215B2 (en) 2021-09-09
KR102469995B1 (ko) 2022-11-24
ECSP18094790A (es) 2019-01-31
AR124916A2 (es) 2023-05-17
MX385054B (es) 2025-03-14
JP7392211B2 (ja) 2023-12-06
SMT202000394T1 (it) 2020-09-10
ZA201808423B (en) 2019-08-28
AU2017273215A1 (en) 2018-10-25
IL262415A (en) 2018-12-31
JP2023172889A (ja) 2023-12-06
TWI849782B (zh) 2024-07-21
UY40612A (es) 2024-02-15
CL2018003323A1 (es) 2019-03-22
RU2021127810A (ru) 2021-10-25
TW201802085A (zh) 2018-01-16

Similar Documents

Publication Publication Date Title
JP7392211B2 (ja) ヘテロアリール置換されたピリジン類及び使用方法
TWI649325B (zh) 用於治療囊狀纖維化之新穎化合物及其醫藥組合物
JP6779992B2 (ja) Ｎ−スルホニル化ピラゾロ［３，４−ｂ］ピリジン−６−カルボキサミドおよび使用法
JP7025556B2 (ja) Ｐｒｃ２阻害剤
CN119654317A (zh) 用于治疗癌症的取代双环杂芳基磺酰胺衍生物
HK40006841A (en) Heteroaryl substituted pyridines and methods of use
HK40006841B (en) Heteroaryl substituted pyridines and methods of use
BR122024019066A2 (pt) Composto de piridina substituída com heteroarila, composições farmacêuticas que compreendem o mesmo e usos do mesmo para tratar fibrose cística
BR112018074815B1 (pt) Composto de piridina substituída com heteroarila
HK1192227B (en) Thiazolopyrimidine compounds
HK1192227A1 (zh) 噻唑并嘧啶化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200515

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210817

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211005

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211026

R150 Certificate of patent or registration of utility model

Ref document number: 6968094

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250